Chemomab shares rise 11.30% premarket after announcing Phase 2 SPRING trial results and maintaining Maxim Group Buy rating.

Chemomab Therapeutics (CMMB) surged 11.30% in premarket trading following the announcement of results from its Phase 2 SPRING trial, a key development for the biotech company. The news summary highlights the trial's significance, while the article references a "laser breakthrough" potentially driving investor optimism. Additionally, Maxim Group maintained a "Buy" rating on the stock, reinforcing positive sentiment. The premarket rally aligns with the company’s recent momentum from prior clinical updates, including FDA clearance for a systemic sclerosis treatment in February 2023 and positive NASH trial data in January 2023, though the immediate catalyst appears to be the newly disclosed Phase 2 results.